Cart
sales@molnova.com
Ogremorphin
CAS No. 352563-21-4
Ogremorphin( —— )
Catalog No. M37230 CAS No. 352563-21-4
Ogremorphin (GPR68-IN-1) is a potent inhibitor of GPR68 with an EC50 of 170 nM, used in the study of autoimmune chronic inflammatory diseases .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 606 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameOgremorphin
-
NoteResearch use only, not for human use.
-
Brief DescriptionOgremorphin (GPR68-IN-1) is a potent inhibitor of GPR68 with an EC50 of 170 nM, used in the study of autoimmune chronic inflammatory diseases .
-
DescriptionOgremorphin (GPR68-IN-1) is a potent GPR68 inhibitor with an EC50of 170 nM. Ogremorphin is extracted from patent WO2020214896 (OGM1), and can be used for autoimmune chronic inflammatory diseases research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetGPR
-
RecptorGPR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number352563-21-4
-
Formula Weight359.44
-
Molecular FormulaC21H17N3OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (139.11 mM; Ultrasonic )
-
SMILESO=C1NC2=CC=C(C=C2C31SC(=NN3)C=4C=CC=C5C=CC=CC54)CC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Charles C. Hong, et al. Small molecule inhibitors of gpcr gpr68 and related receptors. Patent WO2020214896.
molnova catalog
related products
-
cangrelor tetrasodiu...
Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects.cangrelor, a non-sepesific GPR17 antagonist, alleviates pulmonary fibrosis partly by inhibiting macrophage inflammation in mice.
-
Latanoprost acid
Latanoprost acid is a selective agonist of prostanoid receptors and inhibits RANKL-induced osteoclastogenesis and function through the inhibition of c-fos/NFATc1 pathway.
-
Acifran
Acifran (AY 25712) is an HM74A/GPR109A and GPR109B agonist and displays antihyperlipidemic activity.
